Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. The company's marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; and AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis (MS) who have walking disability.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone353-1772-8000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.09 billion
Profitability
Miscellaneous
Employees2,300
Next Earnings Date10/22/2019 (Estimated)
OptionableOptionable
Alkermes (NASDAQ:ALKS) Frequently Asked Questions
What is Alkermes' stock symbol?
Alkermes trades on the NASDAQ under the ticker symbol "ALKS."
How were Alkermes' earnings last quarter?
Alkermes Plc (NASDAQ:ALKS) released its quarterly earnings data on Thursday, July, 25th. The company reported ($0.06) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.26) by $0.20. The business had revenue of $279.90 million for the quarter, compared to analysts' expectations of $251.40 million. Alkermes had a negative net margin of 17.10% and a negative return on equity of 4.13%. The company's revenue for the quarter was down 8.1% compared to the same quarter last year. During the same quarter last year, the company earned $0.29 EPS. View Alkermes' Earnings History.
When is Alkermes' next earnings date?
What guidance has Alkermes issued on next quarter's earnings?
Alkermes updated its FY 2019 earnings guidance on Thursday, July, 25th. The company provided EPS guidance of for the period. The company issued revenue guidance of $1.14-1.19 billion, compared to the consensus revenue estimate of $1.17 billion.
What price target have analysts set for ALKS?
11 Wall Street analysts have issued 1-year price objectives for Alkermes' stock. Their predictions range from $20.00 to $36.00. On average, they anticipate Alkermes' stock price to reach $28.70 in the next year. This suggests a possible upside of 26.2% from the stock's current price. View Analyst Price Targets for Alkermes.
What is the consensus analysts' recommendation for Alkermes?
11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alkermes in the last year. There are currently 2 sell ratings, 7 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Alkermes.
What are Wall Street analysts saying about Alkermes stock?
Here are some recent quotes from research analysts about Alkermes stock:
- 1. According to Zacks Investment Research, "Alkermes posted narrower-than-expected loss and sales beat estimates in the first quarter of 2019. With the increasing traction of Aristada in the market, the company continues to emerge as a leader in the treatment of schizophrenia. This year will be an important one for the company’s late-stage pipeline, highlighted by the planned submission of the NDA for ALKS 3831 and the regulatory review of the recently submitted NDA for diroximel fumarate for multiple sclerosis, with action expected in the fourth quarter. The company also expects to release data from ALKS 4230's anti-tumor response study in 2019. However, Alkermes is highly dependent on manufacturing and/or royalty revenues from partners, which is a concern. Shares have underperformed the industry year to date. Alkermes has a positive record of earnings surprises in recent quarters." (7/19/2019)
- 2. HC Wainwright analysts commented, "Valuation Our $28 price target for Alkermes is based on our sum-of-the-parts NPV valuation based on each of the company’s marketed products and pipeline assets. Our DCF model utilizes a discount rate of 13.1% based on the company’s WACC (Beta of 1.9, equity risk premium of 6.7%)." (5/31/2019)
- 3. Cantor Fitzgerald analysts commented, ": We reiterate the Neutral rating for ALKS stock and are reducing our PT by $5 to $41. We believe the FDA advisory panel view of the ALKS-5461 NDA is a major setback not only for the drug but also to the ability of ALKS to convince investors that the company can develop proprietary therapies of meaningful commercial potential." (11/5/2018)
Has Alkermes been receiving favorable news coverage?
Media headlines about ALKS stock have been trending somewhat positive recently, according to InfoTrie Sentiment. The research firm identifies positive and negative media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Alkermes earned a news impact score of 0.9 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 1.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Alkermes.
Who are some of Alkermes' key competitors?
Some companies that are related to Alkermes include Merck KGaA (MKGAF), BioMarin Pharmaceutical (BMRN), Genmab A/S (GNMSF), Mylan (MYL), Array Biopharma (ARRY), Elanco Animal Health (ELAN), Alnylam Pharmaceuticals (ALNY), Ono Pharmaceutical (OPHLF), Ionis Pharmaceuticals (IONS), Teva Pharmaceutical Industries (TEVA), GALAPAGOS NV/S (GLPG), SAGE Therapeutics (SAGE), Bausch Health Companies (BHC), Perrigo (PRGO) and Jazz Pharmaceuticals (JAZZ).
What other stocks do shareholders of Alkermes own?
Who are Alkermes' key executives?
Alkermes' management team includes the folowing people:
- Mr. Richard F. Pops, Chairman & CEO (Age 57)
- Dr. Floyd E. Bloom, Co-Founder & Director (Age 82)
- Mr. James M. Frates, Sr. VP & CFO (Age 52)
- Mr. David Joseph Gaffin, Sr. VP, Chief Legal Officer, Chief Compliance Officer & Sec. (Age 47)
- Dr. Craig C. Hopkinson, Sr. VP of Medicines Devel. & Medical Affairs and Chief Medical Officer (Age 51)
Who are Alkermes' major shareholders?
Alkermes' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Primecap Management Co. CA (14.80%), Price T Rowe Associates Inc. MD (12.90%), Vanguard Group Inc. (9.28%), BlackRock Inc. (7.09%), BlackRock Inc. (7.09%) and Renaissance Technologies LLC (2.51%). Company insiders that own Alkermes stock include David Joseph Gaffin, David W Anstice, Floyd E Bloom, Iain Michael Brown, James M Frates, Laurie Keating, Mark Stejbach, Michael J Landine, Nancy Wysenski, Paul J Mitchell, Richard F Pops and Shane Cooke. View Institutional Ownership Trends for Alkermes.
Which institutional investors are selling Alkermes stock?
ALKS stock was sold by a variety of institutional investors in the last quarter, including Invesco Ltd., Janus Henderson Group PLC, Janus Henderson Group PLC, Los Angeles Capital Management & Equity Research Inc., Jacobs Levy Equity Management Inc., International Biotechnology Trust PLC, Capital Fund Management S.A. and SG Americas Securities LLC. Company insiders that have sold Alkermes company stock in the last year include David Joseph Gaffin, David W Anstice, Michael J Landine, Paul J Mitchell and Richard F Pops. View Insider Buying and Selling for Alkermes.
Which institutional investors are buying Alkermes stock?
ALKS stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, BlackRock Inc., BlackRock Inc., AQR Capital Management LLC, Price T Rowe Associates Inc. MD, Canada Pension Plan Investment Board, D. E. Shaw & Co. Inc. and Korea Investment CORP. View Insider Buying and Selling for Alkermes.
How do I buy shares of Alkermes?
Shares of ALKS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Alkermes' stock price today?
One share of ALKS stock can currently be purchased for approximately $22.75.
How big of a company is Alkermes?
Alkermes has a market capitalization of $3.57 billion and generates $1.09 billion in revenue each year. The company earns $-139,310,000.00 in net income (profit) each year or ($0.07) on an earnings per share basis. Alkermes employs 2,300 workers across the globe.View Additional Information About Alkermes.
What is Alkermes' official website?
How can I contact Alkermes?
Alkermes' mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE, DUBLIN L2, DUBLIN 4. The company can be reached via phone at 353-1772-8000 or via email at [email protected]
MarketBeat Community Rating for Alkermes (NASDAQ ALKS)
MarketBeat's community ratings are surveys of what our community members think about Alkermes and other stocks. Vote "Outperform" if you believe ALKS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALKS will underperform the S&P 500 over the long term. You may vote once every thirty days.
